The risk of bleeding is associated with the intensity of anticoagulation, ASA dosage, combined use of aspirin and oral anticoagulants and underlying disorders. Therefore, as a general rule, when a patient presents with an MI, one must consider anticoagulation or antiplatelet therapy, based on the clinical risk of thromboembolism and the scientific information available to date. If INR value outside therapeutic range and no signs or symptoms of thromboembolic complications or bleeding, have INR done again in 3 days. Monitor regularly, about once every 4-6 weeks when anticoagulation level is stable. Therapy Bleeding is the most important complication of anticoagulant therapy.
Drug interactions are the commonest cause of significant change in the INR value.
Patients should be informed not to change any medication without a physician's or pharmacist's advice. Adequate monitoring is the key to a successful and safe warfarin therapy. Please refer to the TIG brochure on warfarin therapy. Smith P, et al. Antiplatelet Trialists' Collaboration.